Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
US-9718868-B2 · Aug 1, 2017 · US
Modified SAK gene for the production of recombinant proteins
US9670262B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9670262-B2 |
| Application number | US-201414471400-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 28, 2014 |
| Priority date | Jun 4, 2010 |
| Publication date | Jun 6, 2017 |
| Grant date | Jun 6, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purification of recombinant heterologous proteins from bacterial inclusion bodies using modified SAK.
First claim
Opening claim text (preview).
The invention claimed is: 1. A process for the preparation of heterologous protein of interest in E. coli comprising the steps of: a) preparing a fusion DNA comprising a first DNA encoding modified SAK protein comprising SEQ ID NO. 2 and a second DNA fused in the frame encoding the heterologous protein of interest, b) cloning of the fusion DNA of step a into an expression vector, c) expressing the fusion protein in E. coli cells, d) optionally refolding and purifying the fusion protein; e) enterokinase cleavage of fusion protein, and f) isolating and purifying the protein of interest to obtain pure heterologous protein. 2. The process as claimed in claim 1 , wherein the heterologous protein of interest is parathyroid hormone (1-34).
Assignees
Inventors
Classifications
Platelet-derived growth factor [PDGF] · CPC title
IL-5 · CPC title
t-plasminogen activator (3.4.21.68), i.e. tPA · CPC title
Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates · CPC title
containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9670262B2 cover?
- The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purification of recombinant heterologous proteins from bacterial inclusion bodies using mod…
- Who is the assignee on this patent?
- Lupin Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K14/635. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).